Diabetic Cardiomyopathy in the Elderly

Current Cardiovascular Risk Reports

Volumn 7, Issue 6, 2013, Pages 490-494

  Aronow, Wilbert S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Diabetic cardiomyopathy; Diastolic dysfunction; Dyslipidemia; Ejection fraction; Heart failure; Hyperglycemia; Left ventricular hypertrophy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PERINDOPRIL; PROTEIN KINASE C; SULFONYLUREA; VASCULOTROPIN;

APOPTOSIS; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DYSLIPIDEMIA; ELDERLY CARE; EXERCISE; FIBROSING ALVEOLITIS; FOLLOW UP; GLYCEMIC CONTROL; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HEART MUSCLE PERFUSION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERGLYCEMIA; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; META ANALYSIS (TOPIC); MYOCARDITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

EID: 84887519585     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-013-0351-8     Document Type: Review

References (50)

1. Kannel WB, Hjortland MC, Castelli WP. Role of diabetes in congestive heart failure. The Framingham Study. Am J Cardiol. 1974;34: 29-34.
2. Gustafsson I, Brendorp B, Seibaek M, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol. 2004;43: 771-7.
3. Aronow WS, Ahn C. Incidence of heart failure in 2737 older persons with and without diabetes mellitus. Chest. 1999;115: 867-8.
4. Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function. The Strong Heart Study. Circulation. 2000;101: 2271-6.
5. Galderisi M, Anderson KM, Wilson PWF, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol. 1991;68: 85-9.
6. Lee M, Gardin JM, Lynch JC, et al. Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: the Cardiovascular Health Study. Am Heart J. 1997;133: 36-43.
7. Boyer JK, Thanigaraj S, Schectman KB, Perez JE. Prevalence of ventricular diastolic dysfunction in asymptomatic patients with diabetes mellitus. Am J Cardiol. 2004;93: 395-9.
8. Kosmala W, Kucharski W, Przewlocka-Kosmala M, Mazurek W. Comparison of left ventricular function by tissue Doppler imaging in patients with diabetes mellitus without systemic hypertension vs diabetes mellitus with systemic hypertension. Am J Cardiol. 2004;94: 395-9.
9. Di Stante B, Galandauer I, Aronow WS, et al. Prevalence of left ventricular diastolic function in obese persons with and without diabetes mellitus. Am J Cardiol. 2005;95: 1527-8.
10. dei Cas L, Zuliani U, Maca C, et al. Non-invasive evaluation of left ventricular performance in 294 diabetic patients without clinical heart disease. Acta Diabetol Lat. 1980;17: 145-52.
11. Popirier P, Garneau C, Bogaty P, et al. Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes. Importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care. 2001;24: 5-10.
12. Karvounis HI, Papadopoulos CE, Zaglavara TA, et al. Evidence of left ventricular dysfunction in asymptomatic elderly patients with non-insulin-dependent diabetes mellitus. Angiology. 2004;55: 549-55.
13. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103: 2668-73.
14. von Bibra H, Hansen A, Dounis V, et al. Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart. 2004;90: 1483-4.
15. Markus MR, Stritzke J, Wellmann J, et al. Implications of prevalent and incident diabetes mellitus on left ventricular geometry and function in the ageing heart: the MONICA/KORA Augsburg cohort study. Nutr Metab Cardiovasc Dis. 2011;21: 189-96. Over a 10-year follow-up period long-standing diabetes was associated with accelerated increase in left ventricular mass and left ventricular end-diastolic diameter and a reduction in left ventricular ejection fraction. Long-standing diabetes and incident diabetes which developed during the follow-up period were both associated with worse left ventricular diastolic function.
16. Rijzewijk LJ, van der Meer RW, Lamb HJ, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol. 2009;54: 1524-32.
17. Stefanidis A, Bousboulas S, Kalafatis J, et al. Left ventricular anatomical and functional changes with ageing in type 2 diabetic adults. Eur J Echocardiogr. 2009;10: 647-53.
18. Aboukhoudir F, Rekik S. Left ventricular systolic function deterioration during dobutamine stress echocardiography as an early manifestation of diabetic cardiomyopathy and reversal by optimized therapeutic approach. Int J Cardiovasc Imaging. 2012;28: 1329-39. In diabetics with a normal resting left ventricular ejection fraction and no coronary artery disease or coronary vasospasm, dobutamine infusion during dobutamine stress echocardiography induced a significant deterioration in left ventricular ejection fraction (15% mean reduction), which was largely reversed by tighter glycemic control and addition of perindopril to their usual treatment.
19. Raey DC. Which left ventricular dysfunction is impaired earlier in the evolution of diabetic cardiomyopathy? An echocardiographic study of young type 1 diabetic patients. Diabetes Care. 1994;17: 633-9.
20. Margogato A, Gerundini P, Vicedomini G, et al. Abnormal cardiovascular response to exercise in young asymptomatic diabetic patients with retinopathy. Am Heart J. 1986;112: 554-60.
21. Mildenberger RR, Bar-Schiomo B, Druck MN, et al. Clinically unrecognized dysfunction in young diabetic patients. J Am Coll Cardiol. 1984;4: 234-8.
22. van Heerebeek L, Hamdani N, Handoko L, et al. Diastolic stiffness of the failing diabetic heart. Importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation. 2008;117: 43-51.
23. Nozynski J, Zakliczynski M, Konecka-Mrowka D, et al. Advanced glycation end products in the development of ischemic and dilated cardiomyopathy in patients with diabetes mellitus type 2. Transplant Proc. 2009;41: 99-104.
24. Bodiga VL, Eda SR, Bodiga A. Advanced glycation end products: role in pathology of diabetic cardiomyopathy. Heart Fail Rev. 2013; [Epub ahead of print]. Advanced glycation end products are generated intracellularly and extracellularly as a result of chronic hyperglycemia. After interaction with receptors for advanced glycation end products (RAGEs), events leading to vascular and myocardial damage occur including oxidative stress, increased inflammation, and increased extracellular matrix accumulation, which result in left ventricular systolic and diastolic dysfunction.
25. Liu JW, Liu D, Cui KZ, et al. Recent advances in understanding the biochemical and molecular mechanism of diabetic cardiomyopathy. Biochem Biophys Commun. 2012;427: 441-3. Diabetes-induced metabolites such as glucose, advanced glycation end products, protein kinase C, free fatty acid, oxidative stress, and other related factors are implicated in the pathophysiology of diabetic cardiomyopathy.
26. Kuethe F, Sigusch HH, Bornstein SR, et al. Apoptosis in patients with dilated cardiomyopathy and diabetes: a feature of diabetic cardiomyopathy. Horm Metab Res. 2007;39: 672-6.
27. Isfort M, Stevens SC, Schaffer S, et al. Metabolic dysfunction in diabetic cardiomyopathy. Heart Fail Rev. 2013; [Epub ahead of print].
28. Goyal B, Mehta A. Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfunction. Hum Exp Toxicol. 2013;32: 571-90. Myocardial fibrosis, small vessel disease, and cardiac autonomic neuropathy are major players in the pathophysiology of diabetic cardiomyopathy.
29. Chavali V, Tyagi SC, Mishra PK. Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes. 2013;6: 151-60. The 3 major stages of diabetic cardiomyopathy are; (1) an early stage with cellular and metabolic changes without clinical left ventricular systolic dysfunction; (2) the middle stage with increased apoptosis, an increase in left ventricular size, diastolic dysfunction, and an ejection fraction less than 50%; (3) the late stage with altered microvasculature compliance, increase in left ventricular size, and a reduction in cardiac performance leading to heart failure.
30. Yokoyama I, Ohrake T, Momoura S, et al. Hyperglycemia rather than insulin resistance is related to reduced coronary flow reserve in NIDDM. Diabetes. 1998;47: 119-24.
31. Pikanen OP, Nuutila P, Raitakari S, et al. Coronary flow reserve in young men with IDDM. Diabetes. 1998;47: 248-54.
32. Fein FS, Sonnenblick EM. Diabetic cardiomyopathy. Prog Cardiovasc Dis. 1985;27: 255-70.
33. Blumenthal HT, Alex M, Goldenberg S. A study of lesions of the intramural coronary artery branches in diabetes mellitus. Arch Pathol. 1960;70: 27.
34. Pearce MB, Bullock RT, Kissiar JC. Myocardial small-vessel disease in patients with diabetes mellitus. Circulation. 1973;48 Suppl 4: 6.
35. Zoneraich S, Silverman G, Zoneraich O. Primary myocardial disease, diabetes mellitus and small-vessel disease. Am Heart J. 1980;5: 754-5.
36. Zoneraich S. Small-vessel disease, coronary artery vasodilator reserve, and diabetic cardiomyopathy. Chest. 1988;94: 5-7.
37. Hayat SA, Patel B, Khattar RS, Malik RA. Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. Clin Sci. 2004;107: 539-57.
38. Tesfamariam B, Brown ML, Cohen RA. Elevated glucose impaired endothelium-dependent relaxation by activating protein kinase C. J Clin Invest. 1991;87: 1643-8.
39. Schilling JD, Mann DL. Diabetic cardiomyopathy. Bench to bedside. Heart Fail Clin. 2012;8: 619-31. Cellular and molecular mechanisms leading to diabetic cardiomyopathy include hyperglycemia, dyslipidemia, oxidative stress, abnormal cardiac myocyte calcium handling, hyperactive protein kinase C signaling in the heart, apoptosis, inflammation, fibrosis, and mitochondrial dysfunction.
40. Seferovic PM, Milinkovic I, Ristic AD, et al. Diabetic cardiomyopathy: ongoing controversies in 2012. Herz. 2012;37: 880-6. The pathologic substrate of diabetic cardiomyopathy is myocardial damage, left ventricular hypertrophy, interstitial fibrosis, structural, and functional changes of the small coronary vessels, metabolic abnormality, and autonomic cardiac neuropathy. Hyperglycemia and insulin resistance with hyperinsulinemia and reduced insulin sensitivity contribute to the pathogenesis of cardiomyopathy.
41. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53: 1343-82.
42. Kamalesh M. Heart failure in diabetes and related conditions. J Card Fail. 2007;13: 861-73.
43. Cohen-Solal A, Beauvais F, Logeart D. Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J Card Fail. 2008;14: 615-25.
44. American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care. 2013;36 Suppl 1: S11-66. The American Diabetes Association 2013 guidelines state that a reasonable hemoglobin A1c goal for diabetics is less than 7. 0%. Systolic blood pressure in most diabetics with hypertension should be reduced to less than 140 mm Hg, with use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Serum low-density lipoprotein cholesterol should be reduced to less than 70 mg/dl with statins.
45. Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28: 2345-51.
46. Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure. Diabetes Care. 2007;30: 2148-53.
47. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57: 2037-114.
48. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358: 1887-98.
49. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110: 227-39.
50. Piepoli MF, Davos C, Francis DP, et al. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ. 2004;328: 189.